文献速递脊柱关节炎

乌帕替尼治疗一种抗TNF经治银屑病关节炎患者的疗效与安全性:SELECT-PsA 2事后分析

Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2.
PubMed 文献 · RMD Open · 2026-08-27

SELECT-PsA 2事后分析评估乌帕替尼15 mg每日一次治疗一种抗TNF经治银屑病关节炎患者的长期疗效与安全性至152周。第24周乌帕替尼组ACR20、ACR50、ACR70和MDA应答率均高于安慰剂组,应答维持或改善至152周,未发现新安全信号。

要点

  • 一种抗TNF经治PsA患者中,乌帕替尼15 mg每日一次第24周ACR20应答率57.8% vs 安慰剂21.9%。
  • 第24周MDA应答率24.4% vs 2.9%,应答维持或改善至152周。
  • 疗效与既往TNFi暴露时长总体相似,第2和12周较低疼痛评分预测第152周MDA达标。

核心结论

  • 乌帕替尼15 mg每日一次在一种抗TNF经治银屑病关节炎患者中显示持续疗效和可接受的安全性,与既往TNFi暴露时长无关。

研究设计与样本

  • SELECT-PsA 2研究的事后分析,195例既往暴露于一种TNFi的银屑病关节炎患者随机分配至乌帕替尼15 mg每日一次(90例)或安慰剂(105例,第24周换用乌帕替尼)。

主要发现

  • 第24周乌帕替尼组vs安慰剂组ACR20为57.8% vs 21.9%,ACR50为37.8% vs 9.5%,ACR70为22.2% vs 0%,MDA为24.4% vs 2.9%。
  • 应答维持或改善至第152周,第24周从安慰剂换用乌帕替尼的患者在不同解剖区域达到持续PASI75/90应答。
  • 敏感性和三分位分析显示疗效与既往TNFi暴露时长总体相似,第2和12周较低疼痛评分预测第152周MDA达标。
  • 至第152周未发现新的安全信号,安全性以治疗中出现的不良事件报告。

关键数值与推荐

  • 疗效评估包括ACR20/50/70、MDA、PASI75/90和疼痛,评估至第152周。

临床怎么用

  • 对于一种抗TNF经治的银屑病关节炎患者,乌帕替尼15 mg每日一次可作为治疗选择,早期疼痛改善可能提示长期MDA达标。

局限性

  • 原文为事后分析,未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This post hoc analysis of the SELECT-PsA 2 study evaluated long-term efficacy and safety of upadacitinib 15 mg once daily in patients with psoriatic arthritis (PsA) and exposure to one prior tumour necrosis factor inhibitor (TNFi). METHODS: Patients were randomised to upadacitinib 15 mg once daily or placebo (switched to upadacitinib at week 24). Efficacy assessments 20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), minimal disease activity (MDA), 75%/90% improvement in Psoriasis Area Severity Index Score (PASI75/90), pain) were conducted through 152 weeks. Analyses evaluated the impact of prior TNFi exposure duration, skin improvement by location and early pain response as a predictor of long-term MDA. Safety was reported as treatment-emergent adverse events through week 152. RESULTS: Of 195 patients with exposure to one prior TNFi, 90 and 105 were randomised to upadacitinib 15 mg once daily and placebo, respectively. More patients randomised to upadacitinib 15 mg once daily versus placebo achieved ACR20 (57.8% vs 21.9%), ACR50 (37.8% vs 9.5%), ACR70 (22.2% vs 0%) and MDA (24.4% vs 2.9%) at week 24. Responses were maintained or improved through week 152. Patients who switched from placebo at week 24 achieved sustained PASI75/90 responses across different anatomical regions. Efficacy was generally similar regardless of the duration of prior TNFi exposure in sensitivity and tertile analyses. Lower pain scores at weeks 2 and 12 predicted MDA achievement at week 152. No new safety signals were identified. CONCLUSION: Upadacitinib 15 mg once daily demonstrated sustained efficacy and an acceptable safety profile in patients with PsA and exposure to one prior TNFi, irrespective of the duration of previous TNFi exposure.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Coates LC, Mease P, Kavanaugh A, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2. RMD Open. 2026. PMID: 42660564. doi:10.1136/rmdopen-2025-006655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。